Calcitriol

Summary

Calcitriol (CHEMBL846) is an approved small-molecule bone density conservation agent (ATC A11CC04) targeting VDR; indicated across 40 conditions including psoriasis and chronic kidney disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A11CC04 (+1 more)
• Targets: 1 (VDR)
• Indications: 40 conditions
• Clinical trials: 122
• Chemistry: 416.6 Da · C27H44O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL846
Name	Calcitriol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5280453
ChEBI	CHEBI:17823
ATC	A11CC04, D05AX03
Molecular formula	C27H44O3
Molecular weight	416.6
InChIKey	GMRQFYUYWCNGIN-NKMMMXOESA-N

SMILES: C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C

IUPAC name: trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

ChEBI definition: A hydroxycalciol that is calcidiol in which the pro-S hydrogen of calcidiol is replaced by a hydroxy group. It is the active form of vitamin D3, produced fom calciol via hydoxylation in the liver to form calcidiol, which is subsequently oxidised in the kidney to give calcitriol.

Pharmacological roles (ChEBI): bone density conservation agent, antipsoriatic, immunomodulator, antineoplastic agent, calcium channel modulator, nutraceutical, calcium channel agonist, hormone.

Other ChEBI roles (chemical / environmental): metabolite, human metabolite, mouse metabolite.

Also known as: Calcijex, Calcitriol, Dihydroxyvitamin d 3, RO-215535, Rocaltrol, Silkis, Vectical, calcitriol, SID26719902, SID50110818, CALCITRIOL, SID144205541

Parent form; salt/anhydrous children: CHEMBL578780

Patent coverage: 8,858 distinct patent families (29,522 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
VDR	Vitamin D receptor	Agonist	9.2	0.2%	P11473

Broader ChEMBL bioactivity targets: 32 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Ferritin light chain, Vitamin D3 receptor, Equilibrative nucleoside transporter 1, Progesterone receptor, Cannabinoid receptor 1, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2C, Vitamin D-binding protein, Type-1 angiotensin II receptor, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Prostaglandin G/H synthase 2, Vitamin D3 receptor, Delta-type opioid receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 101 potent at pChembl ≥ 5 of 119 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
VDR	10.97	EC50	0.01	nM	CHEMBL_ACT_2092256
VDR	10.96	EC50	0.01	nM	CHEMBL_ACT_19163666
O42392	10.6	Ki	0.03	nM	CHEMBL_ACT_249109
VDR	10.59	EC50	0.03	nM	CHEMBL_ACT_13388654
P13053	10.4	Ki	0.04	nM	CHEMBL_ACT_16425892
VDR	10.4	IC50	0.04	nM	CHEMBL_ACT_18337127
Q28037	10.32	IC50	0.05	nM	CHEMBL_ACT_22992349
VDR	10.3	IC50	0.05	nM	CHEMBL_ACT_18338410
P13053	10.3	EC50	0.05	nM	CHEMBL_ACT_2001397
P13053	10.3	Ki	0.05	nM	CHEMBL_ACT_2369948
Q28037	10.3	EC50	0.05	nM	CHEMBL_ACT_2391484
VDR	10.22	IC50	0.06	nM	CHEMBL_ACT_15754394
VDR	10.19	Kd	0.07	nM	CHEMBL_ACT_296379
Q28037	10.15	EC50	0.07	nM	CHEMBL_ACT_1819145
VDR	10.15	EC50	0.07	nM	CHEMBL_ACT_18338412
A3RGC1	10.15	Kd	0.07	nM	CHEMBL_ACT_3220470
VDR	10.1	IC50	0.08	nM	CHEMBL_ACT_14642095
VDR	10.02	IC50	0.1	nM	CHEMBL_ACT_18749278
P13053	10	Ki	0.1	nM	CHEMBL_ACT_10958214
P13053	10	Ki	0.1	nM	CHEMBL_ACT_15651768
VDR	10	IC50	0.1	nM	CHEMBL_ACT_16424203
P13053	10	EC50	0.1	nM	CHEMBL_ACT_2129983
VDR	10	EC50	0.1	nM	CHEMBL_ACT_22450484
P13053	10	Ki	0.1	nM	CHEMBL_ACT_2607354
P13053	10	Ki	0.1	nM	CHEMBL_ACT_2640242
P13053	10	Ki	0.1	nM	CHEMBL_ACT_3057721
P13053	10	Ki	0.1	nM	CHEMBL_ACT_5105005
P13053	10	Ki	0.1	nM	CHEMBL_ACT_6371507
P13053	10	Ki	0.1	nM	CHEMBL_ACT_7961343
VDR	9.92	EC50	0.12	nM	CHEMBL_ACT_16424192
VDR	9.8	IC50	0.16	nM	CHEMBL_ACT_18093030
P13053	9.7	ED50	0.2	nM	CHEMBL_ACT_10958230
P13053	9.7	ED50	0.2	nM	CHEMBL_ACT_16425894
P13053	9.7	EC50	0.2	nM	CHEMBL_ACT_2001400
P13053	9.7	EC50	0.2	nM	CHEMBL_ACT_2369979
P13053	9.7	EC50	0.2	nM	CHEMBL_ACT_2607378
P13053	9.7	Ki	0.2	nM	CHEMBL_ACT_5105059
P13053	9.7	ED50	0.2	nM	CHEMBL_ACT_6371469
P13053	9.7	EC50	0.2	nM	CHEMBL_ACT_7962636
VDR	9.52	EC50	0.3	nM	CHEMBL_ACT_16636979
P13053	9.52	EC50	0.3	nM	CHEMBL_ACT_3057723
P13053	9.46	ED50	0.35	nM	CHEMBL_ACT_1039954
VDR	9.46	IC50	0.35	nM	CHEMBL_ACT_16424182
P13053	9.4	ED50	0.4	nM	CHEMBL_ACT_142134
VDR	9.3	ED50	0.5	nM	CHEMBL_ACT_1796473
VDR	9.3	EC50	0.5	nM	CHEMBL_ACT_1819146
VDR	9.3	EC50	0.5	nM	CHEMBL_ACT_2129984
VDR	9.26	EC50	0.56	nM	CHEMBL_ACT_2092255
VDR	9.22	EC50	0.6	nM	CHEMBL_ACT_16424199
VDR	9.15	ED50	0.7	nM	CHEMBL_ACT_1796471
VDR	9.15	IC50	0.7	nM	CHEMBL_ACT_1796472
VDR	9.1	IC50	0.8	nM	CHEMBL_ACT_1995470
VDR	9	EC50	1	nM	CHEMBL_ACT_12102217
VDR	9	EC50	1	nM	CHEMBL_ACT_2129997
VDR	8.95	IC50	1.13	nM	CHEMBL_ACT_16425554
VDR	8.95	IC50	1.13	nM	CHEMBL_ACT_18173015
VDR	8.91	IC50	1.24	nM	CHEMBL_ACT_12109576
VDR	8.91	IC50	1.24	nM	CHEMBL_ACT_24697416
VDR	8.89	IC50	1.3	nM	CHEMBL_ACT_18503014
VDR	8.85	IC50	1.42	nM	CHEMBL_ACT_18809473
VDR	8.82	ED50	1.5	nM	CHEMBL_ACT_1995469
VDR	8.8	EC50	1.6	nM	CHEMBL_ACT_18503049
VDR	8.8	EC50	1.58	nM	CHEMBL_ACT_18809477
VDR	8.8	EC50	1.6	nM	CHEMBL_ACT_22992340
VDR	8.6	EC50	2.5	nM	CHEMBL_ACT_12102218
VDR	8.52	EC50	3	nM	CHEMBL_ACT_12670615
CYP24A1	8.52	EC50	3.02	nM	CHEMBL_ACT_24697411
VDR	8.49	IC50	3.25	nM	CHEMBL_ACT_25726956
VDR	8.48	EC50	3.28	nM	CHEMBL_ACT_12109583
VDR	8.47	EC50	3.4	nM	CHEMBL_ACT_25501778
VDR	8.45	EC50	3.52	nM	CHEMBL_ACT_2092265
VDR	8.4	EC50	3.94	nM	CHEMBL_ACT_16635832
VDR	8.31	EC50	4.9	nM	CHEMBL_ACT_22992360
Q9PTN2	8.26	EC50	5.5	nM	CHEMBL_ACT_14547542
VDR	8.15	EC50	7	nM	CHEMBL_ACT_22992354
VDR	8.11	EC50	7.7	nM	CHEMBL_ACT_13384689
VDR	8.11	EC50	7.7	nM	CHEMBL_ACT_15154257
VDR	8.05	EC50	9	nM	CHEMBL_ACT_16425610
VDR	8.05	EC50	9	nM	CHEMBL_ACT_18173004
VDR	8.03	IC50	9.3	nM	CHEMBL_ACT_13472717
VDR	8	EC50	10	nM	CHEMBL_ACT_2419351
VDR	8	EC50	10	nM	CHEMBL_ACT_2419352
VDR	7.97	EC50	10.8	nM	CHEMBL_ACT_25501764
VDR	7.89	IC50	13	nM	CHEMBL_ACT_3341160
VDR	7.82	EC50	15	nM	CHEMBL_ACT_13472715
GC	7.62	Kd	24	nM	CHEMBL_ACT_3220469
P48281	7	EC50	100	nM	CHEMBL_ACT_19167918
VDR	7	EC50	100	nM	CHEMBL_ACT_26335966
VDR	6.65	EC50	223.4	nM	CHEMBL_ACT_16635837
VDR	6.6	EC50	249.7	nM	CHEMBL_ACT_16635842
VDR	6.49	EC50	321.5	nM	CHEMBL_ACT_15730668
Q63921	6.4	AC50	400	nM	CHEMBL_ACT_25174987
VDR	6.29	EC50	515.2	nM	CHEMBL_ACT_15730690
Q9PTN2	5.92	Kd	1200	nM	CHEMBL_ACT_20678688
PTGS2	5.51	AC50	3100	nM	CHEMBL_ACT_25166768
ADORA3	5.48	AC50	3300	nM	CHEMBL_ACT_25134810
NR1I2	5.25	AC50	5600	nM	CHEMBL_ACT_25188607
VDR	5.19	IC50	6430	nM	CHEMBL_ACT_18809481
SLC6A3	5.05	AC50	9000	nM	CHEMBL_ACT_25124552
P02791	5	Potency	10000	nM	CHEMBL_ACT_4481452

Target pathways

Aggregated over 1 target gene(s): VDR.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Vitamin D (calciferol) metabolism	1	VDR
Nuclear Receptor transcription pathway	1	VDR
SUMOylation of intracellular receptors	1	VDR

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
cell morphogenesis	1
skeletal system development	1
calcium ion transport	1
intracellular calcium ion homeostasis	1
lactation	1
negative regulation of cell population proliferation	1
positive regulation of gene expression	1
negative regulation of keratinocyte proliferation	1
cell differentiation	1
positive regulation of bone mineralization	1
intracellular receptor signaling pathway	1
phosphate ion transmembrane transport	1
nuclear receptor-mediated bile acid signaling pathway	1
mRNA transcription by RNA polymerase II	1

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
psoriasis	4	MONDO:0005083	EFO:0000676
chronic kidney disease	4	MONDO:0005300	EFO:0003884
hypoparathyroidism	4	MONDO:0001220	EFO:0009451

29 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
osteoporosis	3	MONDO:0005298	EFO:0003882
diabetic kidney disease	3	MONDO:0005016	EFO:0000401
fibroma	3	MONDO:0005167	EFO:0002424
osteopetrosis	3	MONDO:0017198	MONDO:0017198
basal cell carcinoma	2	MONDO:0020804	EFO:0004193
breast neoplasm	2	MONDO:0021100	EFO:0003869
hypertensive disorder	2	MONDO:0005044	EFO:0000537
acute kidney injury	2	MONDO:0002492	HP:0001919
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
cholangiocarcinoma	2	MONDO:0019087	EFO:0005221
Klinefelter syndrome	2	MONDO:0006823	EFO:1001006
renal osteodystrophy	2	MONDO:0006946	EFO:1001152
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
prostate carcinoma	2	MONDO:0005159	EFO:0001663
secondary hyperparathyroidism	2	MONDO:0006964	EFO:1001173
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
Crohn disease	1	MONDO:0005011	EFO:0000384
neoplasm	1	MONDO:0005070	EFO:0000616
metastatic melanoma	1	MONDO:0005191	EFO:0002617
postmenopausal osteoporosis	1	MONDO:0008159	EFO:0003854
oral cavity neoplasm	1	MONDO:0021245	EFO:0003868
attention deficit-hyperactivity disorder	1	MONDO:0007743	EFO:0003888
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158
prediabetes syndrome	1	MONDO:0006920	EFO:1001121
opiate dependence	1	MONDO:0005530	EFO:0010702

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 122.

Phase distribution

Phase	Trials
PHASE4	31
PHASE2	30
Not specified	23
PHASE1	15
PHASE3	10
EARLY_PHASE1	6
PHASE1/PHASE2	5
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05902078	PHASE4	RECRUITING	Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
NCT00062699	PHASE4	TERMINATED	Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
NCT00073710	PHASE4	COMPLETED	Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium
NCT00319761	PHASE4	COMPLETED	Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy
NCT00508898	PHASE4	WITHDRAWN	The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria
NCT00664430	PHASE4	TERMINATED	Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects
NCT00712205	PHASE4	UNKNOWN	Vitamin D for the Treatment of Severe Asthma
NCT00752102	PHASE4	COMPLETED	Vitamin D and Coronary Calcification Study
NCT00823303	PHASE4	COMPLETED	Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
NCT00862693	PHASE4	UNKNOWN	Calcitriol in the Treatment of Immunoglobulin A Nephropathy
NCT01012713	PHASE4	COMPLETED	Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis
NCT01115543	PHASE4	COMPLETED	Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism
NCT01205880	PHASE4	COMPLETED	Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis
NCT01265615	PHASE4	COMPLETED	Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
NCT01350934	PHASE4	COMPLETED	A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)
NCT01388517	PHASE4	COMPLETED	Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba
NCT01512862	PHASE4	UNKNOWN	Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients
NCT01561222	PHASE4	UNKNOWN	Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2
NCT01673204	PHASE4	UNKNOWN	Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
NCT01725113	PHASE4	TERMINATED	Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
NCT01748396	PHASE4	COMPLETED	Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol
NCT01765010	PHASE4	UNKNOWN	The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels
NCT01766440	PHASE4	COMPLETED	PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
NCT01768351	PHASE4	COMPLETED	Paricalcitol Effect on Anemia in CKD
NCT01820832	PHASE4	UNKNOWN	Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD
NCT02125279	PHASE4	COMPLETED	Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
NCT02186665	PHASE4	COMPLETED	Plaque Psoriasis Study in Pediatric Subjects
NCT03820518	PHASE4	UNKNOWN	Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia
NCT04038853	PHASE4	COMPLETED	Vitamin D in Fatty Liver Disease
NCT04094805	PHASE4	UNKNOWN	A Multicenter Randomized Study of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP
NCT04801303	PHASE4	COMPLETED	Evaluation of the Effects of Calcitriol’s in the Neurological Symptoms of Friedreich’s Ataxia Patients
NCT00000412	PHASE3	COMPLETED	Osteoporosis Prevention After Heart Transplant
NCT00004402	PHASE3	COMPLETED	Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis
NCT00043576	PHASE2/PHASE3	UNKNOWN	ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
NCT00273338	PHASE3	TERMINATED	DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
NCT00486512	PHASE3	TERMINATED	Chemoprevention of Colorectal Adenomas
NCT00658788	PHASE3	COMPLETED	Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
NCT01384539	PHASE3	COMPLETED	Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
NCT02282813	PHASE3	COMPLETED	Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
NCT02410005	PHASE2/PHASE3	TERMINATED	Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
NCT02859896	PHASE3	TERMINATED	Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
NCT03140449	PHASE3	COMPLETED	Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis
NCT03216564	PHASE3	UNKNOWN	An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes
NCT00001304	PHASE2	COMPLETED	Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
NCT00004043	PHASE2	COMPLETED	Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer
NCT00004340	PHASE2	COMPLETED	Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
NCT00017576	PHASE2	COMPLETED	Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00030069	PHASE2	COMPLETED	Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes
NCT00054522	PHASE2	COMPLETED	Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy
NCT00066885	PHASE1/PHASE2	COMPLETED	Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer
NCT00084864	PHASE2	TERMINATED	Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate
NCT00118066	PHASE2	TERMINATED	Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia
NCT00182741	PHASE2	COMPLETED	Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
NCT00238199	PHASE2	COMPLETED	Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
NCT00301067	PHASE1/PHASE2	COMPLETED	Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
NCT00383487	PHASE2	TERMINATED	A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
NCT00419666	PHASE2	COMPLETED	A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis
NCT00524589	PHASE2	TERMINATED	Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00536770	PHASE2	SUSPENDED	A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
NCT00536991	PHASE1/PHASE2	TERMINATED	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
NCT00623974	PHASE2	TERMINATED	Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia
NCT00763555	PHASE2	COMPLETED	Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
NCT00794547	PHASE1/PHASE2	TERMINATED	Phase I/II Calcitriol in Lung Cancer
NCT00904033	PHASE2	COMPLETED	Calcitriol, Physical Activity, and Bone Health in Cancer Survivors
NCT00953849	PHASE1/PHASE2	COMPLETED	Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
NCT01039181	PHASE2	UNKNOWN	Calcitriol in Advanced Intrahepatic Cholangiocarcinoma
NCT01120119	PHASE2	COMPLETED	Efficacy of Calcitriol in Recent Onset Type 1 Diabetes
NCT01293682	PHASE2	COMPLETED	Effects of High Dose Calcitriol in Breast Cancer Patients
NCT01358045	PHASE2	COMPLETED	Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma
NCT01689441	PHASE2	COMPLETED	Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis
NCT01863641	PHASE2	UNKNOWN	The Effect of Calcitriol on Progress and Activity of Lupus Nephritis
NCT01868750	PHASE2	COMPLETED	Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia
NCT02047799	PHASE2	COMPLETED	Effect of Vitamin D Supplementation on Blood Pressure in Elderly People
NCT02061384	PHASE2	COMPLETED	RA-2 13-cis Retinoic Acid (Isotretinoin)
NCT02224144	PHASE2	COMPLETED	Bone Mass and Strength After Kidney Transplantation
NCT02962102	PHASE2	COMPLETED	Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury
NCT03261336	PHASE2	TERMINATED	Oral Calcitriol With Ketoconazole in CRPC
NCT05765617	PHASE2	COMPLETED	Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients
NCT00004928	PHASE1	COMPLETED	Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
NCT00008086	PHASE1	COMPLETED	Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
NCT00009802	PHASE1	COMPLETED	Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT00010231	PHASE1	COMPLETED	Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00084708	PHASE1	COMPLETED	Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
NCT00238225	PHASE1	COMPLETED	Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00298545	PHASE1	COMPLETED	Effect of Vitamin D and Calcium on Genes in the Colon
NCT00925704	PHASE1	COMPLETED	The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers
NCT01093092	PHASE1	TERMINATED	Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
NCT01235728	PHASE1	COMPLETED	A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)
NCT01969656	PHASE1	COMPLETED	Safety Study of an Oral Vitamin D Analog in Postmenopausal Women
NCT03103750	PHASE1	COMPLETED	Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD
NCT04286529	PHASE1	TERMINATED	Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons
NCT04386811	PHASE1	TERMINATED	Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning.
NCT06261905	PHASE1	COMPLETED	Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System
NCT00585442	EARLY_PHASE1	TERMINATED	Effects of Vitamin D on Renin Expression in Hypertensive Patients
NCT01988116	EARLY_PHASE1	COMPLETED	Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease
NCT03563235	EARLY_PHASE1	UNKNOWN	Clinical Study on Treatment of Postmenopausal Osteoporosis (Kidney Deficiency and Blood Stasis Syndrome) With Xulin Jiangu Granules
NCT03748966	EARLY_PHASE1	COMPLETED	Calcitriol Monotherapy for X-Linked Hypophosphatemia
NCT04643821	EARLY_PHASE1	COMPLETED	NVD in Hypothermic HIE Neonates
NCT04826133	EARLY_PHASE1	TERMINATED	Vitamin D and Cocaine Administration
NCT03249012	Not specified	RECRUITING	Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

9 molecules share ≥1 primary target. Top 9 by shared-target count:

Molecule	Source	Status	Shared targets
CALCIPOTRIENE	ChEMBL	Phase 4 (approved)	VDR
CHOLECALCIFEROL	ChEMBL	Phase 4 (approved)	VDR
DOXERCALCIFEROL	ChEMBL	Phase 4 (approved)	VDR
TACALCITOL	ChEMBL	Phase 4 (approved)	VDR
CURCUMIN	ChEMBL	Phase 3	VDR
MAXACALCITOL	ChEMBL	Phase 3	VDR
SEOCALCITOL	ChEMBL	Phase 3	VDR
TAUROLITHOCHOLIC ACID	ChEMBL	Phase 3	VDR
chenodiol	PubChem	Approved	VDR